Trump orders 'genius' biotechs to British PM's bedside

President Donald Trump gives a speech on HRAs
The president did not name the companies but mentioned they had done work on other viruses, including Ebola and HIV. (White House)

President Donald Trump has asked “leading” U.S. pharmaceutical companies working on experimental COVID-19 treatments to “contact London” and offer help to U.K. Prime Minister Boris Johnson, who is in intensive care after testing positive for the novel coronavirus last month.

“They have arrived in London already. Their London office has whatever they need and we’ll see if we can be of help,” said Trump at a press briefing on Monday, referring to two of “the leading companies.”

The president did not name the companies but mentioned they had done work on other viruses: “Ebola, AIDS, others, they’ve come with the solutions and they have done incredible jobs,” he said. “I’ve asked them to contact London immediately. They have offices in London—major companies—but more than major, more than size, they’re genius.”

Virtual Roundtable

ASCO Explained: Expert predictions and takeaways from the world's biggest cancer meeting

Join FiercePharma for our ASCO pre- and post-show webinar series. We'll bring together a panel of experts to preview what to watch for at ASCO. Cancer experts will highlight closely watched data sets to be unveiled at the virtual meeting--and discuss how they could change prescribing patterns. Following the meeting, we’ll do a post-show wrap up to break down the biggest data that came out over the weekend, as well as the implications they could have for prescribers, patients and drugmakers.

RELATED: Without data, but with Trump praise, FDA issues emergency nod for chloroquine in COVID-19

He said later in the briefing that he had spoken with the heads of four biopharma companies: Amgen, Genentech, Gilead and Regeneron.

When asked by a reporter what sort of treatment the companies were offering, Trump said: “It’s a very complex treatment of things that they’ve just recently developed, and that they have a lot of experience with having to do with something else, but recent for this.”

“They’ve already had meetings with [Johnson’s] doctors and we’ll see whether or not they want to go that route. But when you’re in intensive care, it’s a big deal. So, they’re there and they’re ready,” he added.

Suggested Articles

The FDA named more than two dozen coronavirus antibody tests that should be taken off the market weeks after the agency clamped down on tests.

Inovio CEO J. Joseph Kim is undeterred by short sellers and other detractors who doubt his company can shuttle a COVID-19 DNA vaccine to market.

The machine-learning programs scroll through data to detect hard-to-spot patterns. Yet few have been tested against standard procedures.